Evaluation of prostatic specific antigen (PSA) before and after prostate biopsy. Could this change define the existence of prostate cancer?

PSA change ratio before and after prostate biopsy. Can it predict the need of repeat biopsy?

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12613000716763

Acronym

PSABAPB (PSA Before and After Prostate Biopsy)

Enrollment

210

Registered

2013-07-01

Start date

2013-08-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Prostate biopsy is the most useful diagnostic procedure for prostate cancer. We are going to estimate the PSA change ratio before and after prostate biopsy between two groups of patients. Based on the result of biopsy group A is comprised of patients with benign prostate hyperplasia while group B is comprised of patients with prostate cancer. According to the results we will try to find out new prognostic markers in order to predict which of our patients with negative cancer results in the biopsy are the best candidates for a repeat biopsy.

Interventions

Transrectal ultrasound guided prostate biopsy. A transrectal ultrasound-guided prostate biopsy is a procedure that takes small samples of tissue from prostate gland with the aid of transrectal ultrasound probe. The procedure usually takes 10 to 15 minutes.

Study design

Allocation

Non-randomised trial

Primary purpose

Diagnosis

Eligibility

Sex/Gender

Male

Age

35 Years to No maximum

Healthy volunteers

Inclusion criteria

Serum PSA > 4 ng/ml or abnormal DRE findings

Exclusion criteria

Antiplatelet or anticoagulant medication <5 days before prostate biopsy Bleeding disorder Active UTI Recent urethra catheterization due to acute retention (< 1 month)

Outcome results